EP Patent

EP4201427A1 — Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same

Assigned to Zogenix International Ltd · Expires 2023-06-28 · 3y expired

What this patent protects

Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such a fenfluramine is characterized by the formation of a metabolite including 5-HT<sub>2B</sub> agonists such as norfenfluramine with known …

USPTO Abstract

Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such a fenfluramine is characterized by the formation of a metabolite including 5-HT<sub>2B</sub> agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

Drugs covered by this patent

Patent Metadata

Patent number
EP4201427A1
Jurisdiction
EP
Classification
—
Expires
2023-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Zogenix International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.